Elevated serum BLyS levels in patients with non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 9, 2007, Pages 1869-1871

  Oki, Yasuhiro ^a   Georgakis, Georgios V ^a   Migone, Thi Sau ^b   Kwak, Larry W ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; MEMBRANE PROTEIN; PROTEIN BLYS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; B-CELL ACTIVATING FACTOR; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 34548593570     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701549562     Document Type: Article

References (11)

1. Younes, A. and Kadin, M. E. (2003) Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol, 21, pp. 3526-3534.
2. Kern, C., Cornuel, J. F., Billard, C., Tang, R., Rouillard, D. and Stenou, V. (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood, 103, pp. 679-688.
3. Chadburn, A., Jou, E., Schattner, E. J., Knowles, D. M. and Cerutti, A. (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol, 172, pp. 3268-3279.
4. Klein, B., Tarte, K., Jourdan, M., Mathouk, K., Moreaux, J. and Jourdan, E. (2003) Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol, 78, pp. 106-113.
5. Novak, A. J., Grote, D. M., Stenson, M., Ziesmer, S. C., Witzig, T. E. and Habermann, T. M. (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood, 104, pp. 2247-2253.
6. Kolb, J. P., Kern, C., Quiney, C., Roman, V. and Billard, C. (2003) Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord, 3, pp. 261-286.
7. Novak, A. J., Bram, R. J., Kay, N. E. and Jelinek, D. F. (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: A mechanism for survival. Blood, 100, pp. 2973-2979.
8. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T. and Lugagne, C. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone. Blood, 103, pp. 3148-3157.
9. Novak, A. J., Darce, J. R., Arendt, B. K., Harder, B., Henderson, K. and Kindsvogel, W. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood, 103, pp. 689-694.
10. Oki, Y., Georgakis, G. V., Migone, T. S., Kwak, L. W. and Younes, A. (2007) Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica, 92, pp. 269-270.
11. Cheema, G. S., Roschke, V., Hilbert, D. M. and Stohl, W. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum, 44, pp. 1313-1319.